TCBP

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.0020
Percentage change 0.34	%

Peers: MRK PFE GILD JNJ AMGN REGN BMY VRTX IONS BIIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	0.49M	Perf Week	-7.84%
Market Cap	0.29M	Forward P/E	-	EPS next Y	-0.00	Insider Trans	-	Shs Float	-	Perf Month	-45.82%
Income	-	PEG	-	EPS next Q	0.00	Inst Own	7.50%	Short Float	-	Perf Quarter	-90.49%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.02	Perf Half Y	-94.78%
Book/sh	0.12	P/B	4.70	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf Year	-98.68%
Cash/sh	2.59	P/C	0.23	EPS next 5Y	-	ROE	-	52W Range	0.44 - 56.02	Perf YTD	-98.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.82%	ROI	-	52W High	-98.96%	Beta	0.02
Dividend TTM	-	Quick Ratio	0.79	Sales past 5Y	-15.17%	Gross Margin	-	52W Low	34.23%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	0.79	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	26.01	Volatility	6.96% 17.99%
Employees	41	Debt/Eq	0.83	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.99
Option/Short	No / Yes	LT Debt/Eq	0.67	EPS Q/Q	-	Payout	-	Rel Volume	0.22	Prev Close	0.58
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	1.15M	Price	0.59
SMA20	-7.80%	SMA50	-73.56%	SMA200	-92.81%	Trades		Volume	267,024	Change	0.34%

Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
Dec-04-24 08:30AM	TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial (PR Newswire) +5.83%
Nov-12-24 09:30AM	TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex Grant (PR Newswire)
Oct-30-24 08:30AM	TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements (PR Newswire) -17.90%
Oct-25-24 09:45AM	TCBP Responds to False Social Media Claim (PR Newswire) -19.19%
08:30AM	Loading…
Oct-22-24 08:30AM	TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic (PR Newswire) +14.54%
Oct-03-24 08:30AM	TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening (PR Newswire) +11.66%
Sep-25-24 08:30AM	TCBP Announces Site Opening of Guys and St. Thomas Hospital (PR Newswire)
Sep-24-24 08:45AM	TCBP to Present at the 2024 ThinkEquity Conference in NYC (PR Newswire)
Sep-20-24 04:00PM	TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial (PR Newswire)
04:00PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire)
Sep-12-24 08:30AM	TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial (PR Newswire) +15.60%
Sep-09-24 08:30AM	TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox (PR Newswire) -28.03%
Sep-06-24 04:00PM	TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox (PR Newswire)
Sep-05-24 08:30AM	TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Loading…
Sep-03-24 08:30AM	TCBP Announces Dosing of 5 New Patients in ACHIEVE (PR Newswire) +30.70%
Aug-28-24 05:15PM	TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering (PR Newswire) +17.14% +30.24%
01:50PM	TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications (PR Newswire)
Aug-15-24 01:00PM	TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b) (PR Newswire) +9.31%
11:30AM	TC BioPharm Announces Closing of $2.0 Million Public Offering (PR Newswire)
Aug-13-24 04:30PM	TC BioPharm Announces Pricing of $2.0 Registered Direct Offering (PR Newswire) -7.83% -8.77%
Jul-31-24 08:00AM	TCBP Announces Plan to Implement ADS Ratio Change (PR Newswire) -32.38%
Jul-22-24 08:00AM	TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia (PR Newswire) -5.12%
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-15-24 08:30AM	TCBP Announces Launch of Compassionate Use Program for TCB008 (PR Newswire)
May-06-24 01:01PM	TC BioPharm Announces Exercise of Warrants for 3.1 Million Gross Proceeds (PR Newswire)
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:37AM	Why Is TC Biopharm (TCBP) Stock Up 51% Today? (InvestorPlace)
08:30AM	TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies (PR Newswire)
10:37AM	Loading…
Apr-04-24 10:37AM	Why Is TC Biopharm (TCBP) Stock Up 78% Today? (InvestorPlace) +50.00%
08:32AM	TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies (PR Newswire)
Apr-02-24 08:30AM	TCBP Increasing Treatment Capacity with Expanded Manufacturing Process (PR Newswire)
Mar-19-24 08:30AM	TCBP Adjourns General Meeting Until a Later Date (PR Newswire) -9.88%
Mar-18-24 08:30AM	TCBP Announces Exercise of Series D Warrants For Cash (PR Newswire)
Mar-01-24 08:30AM	Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated 'The Big Biz Show' (PR Newswire) +5.56%
Feb-27-24 05:15PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire) +5.91%
Feb-22-24 09:32AM	TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial (PR Newswire) +11.94%
Feb-15-24 08:30AM	TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe (PR Newswire)
Feb-14-24 08:30AM	TCBP Provides Shareholder Update and Highlights Upcoming Milestones (PR Newswire) -14.05%
Jan-29-24 08:30AM	TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' (PR Newswire) -13.38%
Jan-18-24 08:30AM	TC BioPharm to Present at the Sequire Investor Summit (PR Newswire)
Jan-04-24 08:30AM	TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jan-03-24 08:30AM	TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies (PR Newswire) -26.20%
Dec-22-23 08:30AM	TC BioPharm Announces Closing of $3.5 Million Public Offering (PR Newswire)
Dec-19-23 08:00AM	TC BioPharm Announces Pricing of $3.5 Million Public Offering (PR Newswire) -12.87%
Dec-18-23 11:15AM	TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D (PR Newswire)
Dec-13-23 06:30AM	TC BioPharm Announces Plan to Implement ADS Ratio Change (PR Newswire)
Nov-28-23 11:05AM	TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug (Zacks) -7.62%
Nov-27-23 08:45AM	TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia (PR Newswire) -25.52%
Nov-14-23 10:00AM	TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results (PR Newswire) +11.71%
Nov-02-23 01:30PM	TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials (PR Newswire)
Oct-25-23 08:00AM	TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements (PR Newswire)
Oct-24-23 08:45AM	Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments (PR Newswire) -6.88%
Oct-23-23 08:00AM	TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML (PR Newswire) +9.94%
Sep-27-23 08:00AM	TC BioPharm to Present at the LD Micro Main Event XVI (PR Newswire)
Sep-05-23 08:30AM	TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL) (PR Newswire)
Aug-29-23 08:30AM	TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Jul-31-23 08:30AM	TC BioPharm Maintains Nasdaq Listing (PR Newswire) +12.81%
Jul-06-23 09:08AM	TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast (Newsfile) -6.42%
May-24-23 09:00AM	TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023 (PR Newswire)
May-04-23 06:29AM	TC Biopharm (Holdings) Full Year 2022 Earnings: Beats Expectations (Simply Wall St.) -8.11%
Apr-26-23 08:30AM	TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008 (PR Newswire) -10.14%
Apr-19-23 08:00AM	TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Mar-30-23 04:15PM	TC BioPharm Announces Closing of $5.5 Million Public Offering (PR Newswire)
Mar-28-23 08:05AM	TC BioPharm Announces Pricing of $5.5 Million Public Offering (PR Newswire) -11.68%
Mar-22-23 08:30AM	TC Biopharm Announces Corporate Restructuring, Reduction in Overhead (PR Newswire)
Mar-16-23 12:00PM	TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2) (PR Newswire) +8.40%
Mar-07-23 08:30AM	TC BioPharm Shifts Focus to FDA Clinical Trials (PR Newswire) -9.74%
Feb-23-23 08:30AM	TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer (PR Newswire) -11.13%
Feb-21-23 08:30AM	TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies (PR Newswire) -32.62%
Feb-14-23 08:30AM	TC BioPharm Announces New Chair of the Board, Arlene Morris (PR Newswire) +14.93%
Feb-13-23 04:15PM	TC BioPharm to Reschedule Shareholder Update Call and Webcast (PR Newswire) +6.68%
Feb-07-23 08:30AM	TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort (PR Newswire)
Jan-30-23 08:30AM	TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division (PR Newswire)
Jan-20-23 08:30AM	TC BioPharm to Host Shareholder Update Call (PR Newswire) -11.73%
Jan-19-23 08:30AM	TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) (PR Newswire) -17.46%
Jan-17-23 08:30AM	TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology (PR Newswire) +10.04%
Jan-12-23 06:50AM	Daily Vickers Top Buyers & Sellers for 01/12/2023 (Argus Research) +11.50%
Dec-12-22 09:00AM	TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update (PR Newswire)
Nov-30-22 06:43PM	TC BioPharm Announces Closing of $7.35 Million Private Placement (PR Newswire)
Nov-28-22 08:00AM	TC BioPharm Announces $7.35 Million Private Placement (PR Newswire) -31.91%
Nov-22-22 08:00AM	TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia (PR Newswire)
Nov-21-22 05:55AM	TC Biopharm (Holdings) Plc's (NASDAQ:TCBP) biggest owners are individual investors who got richer after stock soared 11% last week (Simply Wall St.) -18.63%
Oct-26-22 08:30AM	TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise (PR Newswire)
Oct-03-22 08:30AM	TC BioPharm to Present at Upcoming Investor Conferences (PR Newswire)
Sep-13-22 09:30AM	TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune® (PR Newswire)
Aug-22-22 08:30AM	TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Jul-25-22 08:30AM	TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit (PR Newswire)
Jul-08-22 08:30AM	TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" (PR Newswire)
Jun-07-22 04:00PM	TC Biopharm Announces Closing of $4 Million Underwritten Public Offering (PR Newswire)
Jun-02-22 06:10PM	TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering (PR Newswire) -8.90% -36.07%
May-31-22 10:00AM	TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally (PR Newswire) -8.41%
May-23-22 08:30AM	Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market (PR Newswire) +5.36%
May-18-22 08:30AM	TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts (PR Newswire) +13.41%
May-03-22 08:30AM	TC BioPharm Invited to Present at LD Micro Conference (PR Newswire)
Apr-26-22 08:45AM	TC BioPharm to Participate in Upcoming Conferences (PR Newswire)
Apr-21-22 08:00AM	TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day (PR Newswire) -8.21%
Apr-06-22 10:03AM	TC BioPharm Secures CryoTC Trademark For Cell Freezing Process (Benzinga) +7.74%
08:30AM	TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process (PR Newswire)

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TC BioPharm (Holdings) plc ADR

Upgrade your FINVIZ experience